Sparked by a flurry of executive orders in the first week of taking power, and evolving at dizzying pace, the new US administration has taken a wrecking ball to health-related services and research ...

Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

By Dr. Liji Thomas, MD New recommendations address advances in immunosuppressive therapies and highlight antiviral prophylaxis for high-risk patients. Study: AGA Clinical Practice Guideline on the ...

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus ... either positive for the HBV surface antigen (HBsAg) or HBV core antibody (anti-HBc).

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat chronic ...

Brelovitug (BJT-778) is a fully human immunoglobulin G1 monoclonal antibody designed to target hepatitis B surface antigen and neutralize and remove HBV and HDV virions. The company reports that ...